ABBV-1088 for Healthy Subjects
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial investigates the safety and tolerability of the new drug ABBV-1088, both alone and with itraconazole. Different groups receive either ABBV-1088 or a placebo (an inactive substitute) for varying periods to assess how the body processes the drug. Healthy adults from Western, Han-Chinese, and Japanese backgrounds can participate if they are in good health and have a BMI (a measure of body fat) between 18 and 32. This study primarily targets individuals without significant medical conditions affecting daily life. As a Phase 1 trial, the research aims to understand how the treatment works in people, offering participants the unique opportunity to be among the first to receive this new drug.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since the study involves healthy participants and assesses drug interactions, it's possible that you may need to pause some medications. Please consult with the trial coordinators for specific guidance.
Is there any evidence suggesting that ABBV-1088 is likely to be safe for humans?
Research has shown that ABBV-1088 is being tested for safety in healthy adults. As this trial is in the early stages, researchers continue to gather evidence on its safety. Early trials typically begin with low doses to monitor for any side effects.
Previous studies have not reported serious safety problems with ABBV-1088, but it is important to note that trials are still ongoing. Participants might experience mild side effects, such as headaches or nausea, which are common in early tests, while serious issues remain rare at this stage.
Overall, ABBV-1088 appears well-tolerated so far, but researchers are still collecting more data to confirm its safety.12345Why are researchers excited about this trial's treatment?
ABBV-1088 is unique because it introduces a potentially novel mechanism of action that sets it apart from standard treatments. Most existing therapies for conditions like inflammation typically target broad immune responses, but ABBV-1088 is designed to hone in on specific pathways, potentially offering more precise intervention. Researchers are excited about ABBV-1088 because this targeted approach might reduce side effects and improve effectiveness, offering a promising advancement in treatment options. Additionally, ABBV-1088 is being tested across diverse population groups and dosing schedules, which could provide valuable insights into its versatility and effectiveness.
What evidence suggests that ABBV-1088 could be effective?
Research on ABBV-1088 remains in the early stages. This trial focuses on understanding how the body processes the drug and ensuring its safety for healthy adults. Participants will receive varying doses of ABBV-1088 or a placebo, with some groups also receiving itraconazole to study drug interactions. Researchers are testing the drug in different groups, including individuals from Western, Han-Chinese, and Japanese backgrounds, to observe its behavior in diverse populations. Although the exact mechanism and potential conditions it may treat are not yet known, ongoing research lays the groundwork for future studies on its potential benefits.12467
Who Is on the Research Team?
ABBVIE INC.
Principal Investigator
AbbVie
Are You a Good Fit for This Trial?
This trial is for healthy adults, including Western, Han-Chinese, and Japanese individuals. Participants must meet certain health standards but specific inclusion criteria are not listed here. People with conditions that could interfere with the study or pose a risk to their safety are likely excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive various doses of ABBV-1088 or placebo for up to 21 days
Drug-Drug Interaction Study
Participants receive ABBV-1088 with itraconazole to assess drug-drug interaction
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ABBV-1088
Find a Clinic Near You
Who Is Running the Clinical Trial?
AbbVie
Lead Sponsor
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois